IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
Clinical safety rating: avoid
ACE inhibitors and ARBs may have diminished antihypertensive effect Increases risk of serious cardiovascular thrombotic events and GI bleeding.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
| Metabolism | Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Phenylephrine undergoes oxidative deamination via monoamine oxidase (MAO) and conjugation with sulfate or glucuronide. |
| Excretion | Ibuprofen: Renal elimination of metabolites (90%) and unchanged drug (1-10%); biliary/fecal excretion minor. Phenylephrine: Renal elimination (80-85% as inactive metabolites, 2-3% unchanged); biliary/fecal negligible. |
| Half-life | Ibuprofen: 2-4 hours (prolonged in overdose or hepatic impairment). Phenylephrine: 2-3 hours (clinical activity may persist longer due to vasoconstrictive effects). |
| Protein binding | Ibuprofen: 99% bound to albumin. Phenylephrine: 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Ibuprofen: 0.1-0.2 L/kg (low, reflecting high protein binding). Phenylephrine: 0.2-0.5 L/kg (moderate, distributes to tissues). |
| Bioavailability | Ibuprofen: Oral 80-100% (immediate-release); food delays absorption. Phenylephrine: Oral 38-50% (first-pass metabolism by MAO; OTC formulation 100% relative to reference). |
| Onset of Action | Ibuprofen: Oral 30-60 min. Phenylephrine: Oral 15-30 min. |
| Duration of Action | Ibuprofen: 4-6 hours (pain/fever). Phenylephrine: 4-6 hours (decongestion); tolerance may develop with prolonged use. |
| Molecular Weight | Ibuprofen: 206.28 Da; Phenylephrine hydrochloride: 203.67 Da |
1 tablet (ibuprofen 200 mg/phenylephrine HCl 10 mg) orally every 4-6 hours as needed, not to exceed 6 tablets per 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: Avoid use or reduce dose/frequency; contraindicated if GFR <30 mL/min for ibuprofen component. GFR <15 mL/min: Contraindicated. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Caution; reduce dose or extend interval (specific guidance not established). Child-Pugh C: Avoid use due to increased risk of hepatotoxicity and fluid retention. |
| Pediatric use | Not recommended in children under 12 years of age. For children ≥12 years: Same as adult dosing (1 tablet every 4-6 hours, max 6 tablets/day) based on ibuprofen 200 mg/phenylephrine 10 mg. |
| Geriatric use | Start at lowest effective dose (e.g., 1 tablet every 6-8 hours). Monitor renal function and cardiovascular status; avoid in those with uncontrolled hypertension, CAD, or heart failure. Maximum daily dose not to exceed 3 tablets due to increased sensitivity to phenylephrine and ibuprofen side effects. |
| 1st trimester | Ibuprofen: Avoid due to potential increased risk of miscarriage and cardiac defects; Phenylephrine: Avoid due to possible association with fetal malformations and reduced uterine blood flow. |
| 2nd trimester | Ibuprofen: Use with caution, preferred NSAID if necessary for short duration; Phenylephrine: Avoid due to vasoconstriction and potential fetal hypoxia. |
| 3rd trimester | Ibuprofen: Avoid after 30 weeks due to risk of premature closure of ductus arteriosus and oligohydramnios; Phenylephrine: Avoid due to risk of uterine hypertonus and fetal distress. |
Clinical note
ACE inhibitors and ARBs may have diminished antihypertensive effect Increases risk of serious cardiovascular thrombotic events and GI bleeding.
| FDA category | Positive |
| Placental transfer | Ibuprofen: Crosses placenta extensively; Phenylephrine: Limited human data, but likely crosses due to low molecular weight and lipophilicity. |
■ FDA Black Box Warning
NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use. NSAIDs are contraindicated in patients with recent coronary artery bypass graft (CABG) surgery.
| Common Effects | fever |
| Serious Effects |
Third trimester of pregnancy (ibuprofen component due to ductus arteriosus closure risk)Severe hypertension or hypertensive crisis (phenylephrine component)Concurrent use of MAO inhibitors or within 14 daysKnown hypersensitivity to ibuprofen, phenylephrine, or any componentActive peptic ulcer disease or GI bleeding (ibuprofen)Severe coronary artery disease or angina (phenylephrine)Narrow-angle glaucoma (phenylephrine)
| Precautions | Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs cause increased risk of serious GI adverse events including bleeding, ulceration, and perforation. Avoid in patients with severe hypertension or cardiovascular disease. Use with caution in patients with hyperthyroidism, diabetes, or prostatic hypertrophy due to phenylephrine. |
Loading safety data…
| Breastfeeding | Ibuprofen is excreted into breast milk in low amounts and is considered compatible with breastfeeding; Phenylephrine is poorly excreted into breast milk, but oral use may reduce milk production due to vasoconstriction. Use with caution and monitor infant for irritability or drowsiness. |
| Lactation Rating | L2 (Safer) for short-term use; overall rating due to phenylephrine potential effects: L3 (Moderately Safe) with caution. |
| Teratogenic Risk | First trimester: NSAIDs associated with increased risk of miscarriage and cardiac defects. Second trimester: Avoid due to risk of oligohydramnios and fetal renal dysfunction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. |
| Fetal Monitoring | Monitor amniotic fluid index, fetal renal function, and ductus arteriosus patency via ultrasound if used in second/third trimester. Also monitor maternal blood pressure due to phenylephrine. |
| Fertility Effects | NSAIDs like ibuprofen may impair female fertility by inhibiting prostaglandin synthesis, interfering with ovulation and implantation. Reversible upon discontinuation. |
| Food/Dietary | Avoid alcohol; may increase risk of GI bleeding and hepatic toxicity. Limit caffeine intake as it may exacerbate stimulant effects of phenylephrine. High-sodium foods may counteract antihypertensive effects and increase fluid retention. Grapefruit juice may alter ibuprofen metabolism; avoid large quantities. |
| Clinical Pearls | Ibuprofen is an NSAID that inhibits COX-1 and COX-2, reducing prostaglandin synthesis; phenylephrine is a selective alpha-1 adrenergic agonist causing vasoconstriction. Use with caution in patients with hypertension, cardiovascular disease, or renal impairment due to synergistic vasoconstrictive and sodium-retentive effects. Avoid in patients on MAOIs or within 2 weeks of discontinuation. Monitor blood pressure in elderly or those with pre-existing hypertension. |
| Patient Advice | Take with food or milk to reduce risk of stomach upset. · Do not exceed 6 doses in 24 hours; maximum duration 7 days. · Avoid alcohol, which increases risk of gastrointestinal bleeding. · Discontinue and seek medical help if symptoms worsen, fever persists >3 days, or pain >10 days. · Do not use if you have high blood pressure, heart disease, thyroid disease, diabetes, or difficulty urinating due to prostate enlargement unless directed by a doctor. · May cause drowsiness or dizziness; avoid driving or operating machinery until effects known. |